Distinguishing cancer-associated missense mutations from common polymorphisms - PubMed (original) (raw)
Distinguishing cancer-associated missense mutations from common polymorphisms
Joshua S Kaminker et al. Cancer Res. 2007.
Abstract
Missense variants are commonly identified in genomic sequence but only a small fraction directly contribute to oncogenesis. The ability to distinguish those missense changes that contribute to cancer progression from those that do not is a difficult problem usually only accomplished through functional in vivo analyses. Using two computational algorithms, Sorting Intolerant from Tolerant (SIFT) and the Pfam-based LogR.E-value method, we have identified features that distinguish cancer-associated missense mutations from other classes of missense change. Our data reveal that cancer mutants behave similarly to Mendelian disease mutations, but are clearly distinct from either complex disease mutations or common single-nucleotide polymorphisms. We show that both activating and inactivating oncogenic mutations are predicted to be deleterious, although activating changes are likely to increase protein activity. Using the Gene Ontology and data from the SIFT and LogR.E-value metrics, a classifier was built that predicts cancer-associated missense mutations with a very low false-positive rate. The classifier does remarkably well in a number of different experiments designed to distinguish polymorphisms from true cancer-associated mutations. We also show that recurrently observed mutations are much more likely to be predicted to be cancer-associated than rare mutations, suggesting that our classifier will be useful in distinguishing causal from passenger mutations. In addition, from an expressed sequence tag-based screen, we identified a previously unknown germ line change (P1104A) in tumor tissues that is predicted to disrupt the function of the TYK2 protein. The data presented here show that this novel bioinformatics approach to classifying cancer-associated variants is robust and can be used for large-scale analyses.
Similar articles
- CanPredict: a computational tool for predicting cancer-associated missense mutations.
Kaminker JS, Zhang Y, Watanabe C, Zhang Z. Kaminker JS, et al. Nucleic Acids Res. 2007 Jul;35(Web Server issue):W595-8. doi: 10.1093/nar/gkm405. Epub 2007 May 30. Nucleic Acids Res. 2007. PMID: 17537827 Free PMC article. - A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
Caligo MA, Bonatti F, Guidugli L, Aretini P, Galli A. Caligo MA, et al. Hum Mutat. 2009 Jan;30(1):123-33. doi: 10.1002/humu.20817. Hum Mutat. 2009. PMID: 18680205 - Predicting the oncogenicity of missense mutations reported in the International Agency for Cancer Research (IARC) mutation database on p53.
Gorlov IP, Gorlova OY, Amos CI. Gorlov IP, et al. Hum Mutat. 2005 Nov;26(5):446-54. doi: 10.1002/humu.20242. Hum Mutat. 2005. PMID: 16173033 - Computational prediction of the effects of non-synonymous single nucleotide polymorphisms in human DNA repair genes.
Nakken S, Alseth I, Rognes T. Nakken S, et al. Neuroscience. 2007 Apr 14;145(4):1273-9. doi: 10.1016/j.neuroscience.2006.09.004. Epub 2006 Oct 19. Neuroscience. 2007. PMID: 17055652 Review. - AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance.
Spanakis E, Milord E, Gragnoli C. Spanakis E, et al. J Cell Physiol. 2008 Dec;217(3):605-17. doi: 10.1002/jcp.21552. J Cell Physiol. 2008. PMID: 18726898 Review.
Cited by
- Enhancing Missense Variant Pathogenicity Prediction with MissenseNet: Integrating Structural Insights and ShuffleNet-Based Deep Learning Techniques.
Liu J, Chen Y, Huang K, Guan X. Liu J, et al. Biomolecules. 2024 Sep 2;14(9):1105. doi: 10.3390/biom14091105. Biomolecules. 2024. PMID: 39334871 Free PMC article. - Tyk2 is a tumor suppressor in colorectal cancer.
Moritsch S, Mödl B, Scharf I, Janker L, Zwolanek D, Timelthaler G, Casanova E, Sibilia M, Mohr T, Kenner L, Herndler-Brandstetter D, Gerner C, Müller M, Strobl B, Eferl R. Moritsch S, et al. Oncoimmunology. 2022 Sep 26;11(1):2127271. doi: 10.1080/2162402X.2022.2127271. eCollection 2022. Oncoimmunology. 2022. PMID: 36185806 Free PMC article. - PON-All: Amino Acid Substitution Tolerance Predictor for All Organisms.
Yang Y, Shao A, Vihinen M. Yang Y, et al. Front Mol Biosci. 2022 Jun 16;9:867572. doi: 10.3389/fmolb.2022.867572. eCollection 2022. Front Mol Biosci. 2022. PMID: 35782867 Free PMC article. - TYK2 in Cancer Metastases: Genomic and Proteomic Discovery.
Borcherding DC, He K, Amin NV, Hirbe AC. Borcherding DC, et al. Cancers (Basel). 2021 Aug 19;13(16):4171. doi: 10.3390/cancers13164171. Cancers (Basel). 2021. PMID: 34439323 Free PMC article. Review. - Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation.
Patil K, Jordan EJ, Park JH, Suresh K, Smith CM, Lemmon AA, Mossé YP, Lemmon MA, Radhakrishnan R. Patil K, et al. Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):e2019132118. doi: 10.1073/pnas.2019132118. Proc Natl Acad Sci U S A. 2021. PMID: 33674381 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources